Personalized Cancer Medicine
NCGC Projects
A National Research and Innovation Platform for Personalized Cancer Medicine
The project will establish the required general technology, methodology and interpretation procedures, which will be commonly shared, for utilizing the mutation profile of the tumor to guide the adaptation of cancer treatment to the individual patient.
Malignant melanomas
Our first project was the sequencing of all genes (EKSOM) in 114 melanomas and normal samples from all patients. These data are now being published. The project is based at Haukeland University Hospital. Malignant melanomas respond generally poor in systemic...
Colorectal cancer
The exomes of 100 pairs of normal/cancer patient samples have been sequenced, and are now being analyzed for mutations. This project is performed at Oslo University Hospital.
Multiple Myeloma
Myelomatosis and chronic lymphatic leukaemia (CLL) are the most common cancers of the blood, with 370 annual new cases.
Lymphoma
We are about to determine the sequence of all genes in several subtypes of Lymphoma. The project is performed at Oslo University Hospital.
Leukaemia
We are currently planning the sequencing of the eksom of groups of specifically selected subtypes of leukaemia. The project is based at Haukeland University Hospital.
Sarcoma
Sarcomas are an uncommon type of cancer, but it is quite frequent in young patients. The Sarcoma project is prospective in that we will systematically collect samples and analyze mutations in patients recruited from around the country. It is crucial that we are...
Prostate Cancer
Heterogeneity of genetic changes in multifocal prostate cancer
Breast cancer
A study of metastatic breast cancer is on-going, with the analysis of a second cohort under way.
Ovarian Cancer
Eggstokkreft er den mest dødelige gynekologisk kreftsykdommen. Symptomene på eggstokkreft kommer sent og er ofte lite spesifikke. Som følge av dette blir to tredjedeler av pasientene diagnostisert sent i sykdomsforløpet.
Bioinformatics
A crucial part of the work is to analyse the DNA code in the most efficient and precise way. Each step of the process requires optimisation to prevent errors in the readout.
Technology
– Next generation sequencing of cancer genes Leonardo A. Meza-Zepeda, who is in charge of the Cancer Genomics Core facility at OUS, is also the leader of the NCGC Genomics Platform. In the Research Building at the Norwegian Radium Hospital in Oslo and at...
Health economics
Health economics is focused on the allocation of limited resources in the health sector, so that one can achieve both a fair distribution while maximizing health. Our research on cancer genomics aims to answer two important research questions: 1) Is...
Ethics
The work-package for ethics, law and public aspects is led by professor Jan Helge Solbakk at the public health department at the University of Oslo. The Norwegian Biotechnology Advisory Board and the Oslo Cancer Cluster are also involved in this...
Public dialogs
The Norwegian Biotechnology Advisory Board led by Director Sissel Rogne participates in the ethical research projects as well as the public discussions. The Cancer Society contributes wit the perspective of the patient.
Law
The project «Legal Regulation of Information Processing Relating to Personalized Cancer Medicine» is led by Professor Jan Helge Solbakk. The project is a collaboration between The Centre for Medical Ethics at The Medical Faculty, University of Oslo and The...
Innovative networks
The Oslo Cancer Cluster actively supports the Norwegian Cancer Genomics Consortium (NCGC), and has done so since the start. The Oslo Cancer Cluster Management Team in close collaboration with several members, was vital in supporting the birth of the NCGC and is...